To write your Senator/Representative, please fill out the letter below including your name, condition/relationship to a patient, as well as your full address, and send to advocacy@gbs-cidp.org Sample Letter: Dear Rep./Sen. _____________, I am a constituent living with [Condition]. Thank you for your leadership on patient care and public health issues. I am reaching out…
Behind every treatment plan is a nurse who will listen, support, and walk beside patients through each stage of their journey. In this webinar, Hannah Smith, a neuromuscular nurse at Northern Care Alliance NHS Foundation in London, United Kingdom with experience in administering IVIG, SCIG, and other immunotherapy treatments, will share what it’s really like…
Living with CIDP: Matthew’s Patient Journey and an Overview of an IVIg Treatment Option for Adults with CIDP This program is sponsored by Pfizer, Inc. Now Available to Watch On Demand Join Chelsey Fix, Director of Research and Advocacy from the GBS|CIDP Foundation International, a neurologist, and a person living with CIDP for the online…
A researcher from Yale University is conducting a short, anonymous survey to learn more about how patients with CIDP have responded to Efgartigimod (also known as Vyvgart hytrulo). Your feedback will help us better understand its effects on symptoms, side effects, quality of life, and the overall treatment experience. This information will be invaluable in…
Going into the GBS|CIDP Foundation International’s 2025 Symposium in Denver, I was prepared for a lot. Fellow staff members and patients told me about how inspiring it was, and how much fun I would have interacting with our community in person. Coming back, I can happily say that all of this came true and more….
Missed the biennial GBS|CIDP Foundation International Symposium? You can still catch up through this engaging conversation with Dr. Aaron Zelikovich, who recently completed his fellowship in neuromuscular disease. In this candid recap, he revisits key lessons from the symposium, highlights his favorite moments, and offers reflections on his own journey from fellow to neuromuscular attending.
Step inside the 2025 GBS/CIDP Symposium with a volunteer’s eyes — where research and human connection collided in unforgettable ways. Chris Willard shares how patient stories, caregiver voices, and real-world breakthroughs made the gathering feel more like a movement than a conference. From the launch of the new Interdisciplinary Health Committee to moments of vulnerability…
We’re proud to highlight Lucy, our volunteer from Bulgaria, whose story of resilience continues to inspire. After her own experience with GBS, Lucy has dedicated her time to supporting others in the community and spreading awareness across borders. You can read about the start of her journey in raising awareness here, where she shares how…
The MIgGRATE Study is evaluating an investigational immunoglobulin G (IgG) drug called TAK-881 as a potential treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). TAK-881 is a subcutaneous IgG treatment with a higher IgG concentration than HYQVIA®, which will allow for a smaller amount of the IgG Treatment to be administered under the skin. TAK-881 has…
In 2025, we established the Interdisciplinary Health Committee for GBS, CIDP, and MMN, a collaborative team of healthcare professionals dedicated to providing comprehensive, patient-centered care for individuals diagnosed with Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The purpose of this committee is to provide guidance and resources beyond clinical…
Recently, we visited the Capitol to raise awareness of our patient community living within the United States, and advocate for our bill H.R. 1143—the Medicare IVIG Access Enhancement Act of 2025. This act would amend Title XVIII of the United States Social Security Act to expand coverage of the in-home administration of intravenous immunoglobulin (IVIG)…
For US Audience Only A Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adultswith Multifocal Motor Neuropathy (MOMENTUM) What is this trial about? The MOMENTUM study is testing a new medicine called DNTH103 to see if it can help people withMMN (Multifocal Motor Neuropathy). What is MMN? This can cause: About the…
We’re headed back to Australia! The GBS|CIDP Foundation International is excited to announce that we are headed back to Australia for a Regional Conference in Melbourne! Our last regional gathering in Australia was held in Sydney in 2019, and we are thrilled to return and reconnect with patients, families, and medical professionals from across the…
In this episode, we focus on the role of physical therapy (PT) in the recovery and long-term management of Guillain Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and related variants. The discussion explores how PT supports patients across different stages of care—fromstabilization in acute settings to restoring independence and fine-tuning…
Pagination
Spotlight
